GENENTECH, INC for GENENTECH INC
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
trade Promotion Authority; Issues relating to U.S. trade policy;
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHERINE RAAB | Director |
Taxation/Internal Revenue Code TAX
Issues related to tax eform and tax extenders; corporate tax return; Issues relating to corporate tax reform including the R&D tax credit and taxation of foreign-owned corporations
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
Copyright/Patent/Trademark CPT
intellectual property & process patent issues; MMM: Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; Issues related to 340B
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| KATHERINE RAAB | Director |
Health Issues HCR
: 340B, Patent Terms, Appropriations, Pandemic Preparedness, Tamiflu Stockpile; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectivness research, and FDA approval of follow-on biologics; Publaw 111-152, the Health Care and Education Reconcilation Act of 2010 - Implementation issues related Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit; Meetings with Administration and congressional staff on coverage/payment issues related to cancer biotherapeutics, 340B program; Meetings with Administration staff concerning the President's precision medicine initiative; Issues related to the implementation of the follow-on biologiecs provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; 21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); issues concerning implementationof Patient Protection and Afforedable Care Act; Drug pricing under 340B program; : Implementation issues related to the Pharmaceutical Quality, Security and Accountabilty Act (P.L. 113-54) S. 2007, Preventing Regulatory Overreach to Enhance Care Technology Act of 2014, Cancer Patient Protection Act of 2013 pharma supply chain issues, issues related to the 340B Program;
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| KATHERINE RAAB | Director |
Medicare/Medicaid MMM
Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics; HR 1470 and S.810, the SGR Repeal and Medicare Provider Payment Modernization Act of 2015 - Medicare physician payment reform, payment for Part B drugs; Pbulic Law 114-110, the Medicare Access and CHIP Reauthorization Act - Medicare physician payment reform and CHIP extension, payment for PART B drugs; Concerns regarding Medicare policies for Part B drugs. Issues related to the 340B Drug discount program; Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; Issues related to 340B; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligible demonstratins and Medicare Part B reimbursement for physicians and related provisions of The Affordable Care Act;
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| ANNA GRIFFIN | Sr. Director |
Budget/Appropriations BUD
Issues related to FDA & HHS program funding, FY16 Labor Health and Human Services, and Education, and Related Agencies, and FY 16 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Bills.;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNA GRIFFIN | Sr. Director |
Pharmacy PHA
Public Law 111-148, the Patient Protection and Affordable Care Act 0 Implementation issues related to FDA approval of follow on biologics and length of data exclusivity period, 340B drug pricing program, structure of the Medicare prescription drug benefit.; Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid reimbursement, fees assessed on the pharmaceutical industry, design and structure of the Medicare prescription; General issues and congressional oversight related to FDA approval and CMS coverage decisions regarding Avastin and Lucentis.; Held discussions with Administration staff about 340B program requirements onparticipating pharmaceutical manufacturers., Held preliminary discussion with Administration staff on anti-viral drugs in the strategic national stockpile.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| ANNA GRIFFIN | Sr. Director |
| KATHERINE RAAB | Director |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.